Background:Autoimmune activation and deregulated apoptosis of T lymphocytes are involved in multiple sclerosis (MS). c-Jun N-terminal kinase (JNK) plays a role in T-cell survival and apoptosis.
Objectives:The aim of this work was to investigate the role of the JNK-dependent apoptosis pathway in relapsing–remitting MS (RRMS).
Methods:The immunomodulatory effect of AS602801, a JNK inhibitor, was firstly evaluated on activated peripheral blood mononuclear cells (PBMCs) from healthy volunteers (HVs) and secondly in unstimulated purified CD4+, CD8+ and CD11b+ cells from RRMS patients and HVs. Moreover JNK/inflammation/apoptosis related genes were investigated in RRMS and HV samples.
Results:In activated PBMCs from HVs, we showed that AS602801 blocked T-lymphocyte proliferation and induced apoptosis. In RRMS CD4+ and CD8+ cells, AS602801 induced apoptosis genes and expression of surface markers, while in RRMS CD11b+ cells it induced expression of innate immunity receptors and co-stimulatory molecules. Untreated cells from RRMS active-phase patients significantly released interleukin-23 (IL-23) and interferon-gamma (IFN-γ) and expressed less apoptosis markers compared to the cells of HVs. Moreover, gene expression was significantly different in cells from RRMS active-phase patients vs. HVs. By comparing RRMS PBMCs in the active and stable phases, a specific genomic signature for RRMS was indentified. Additionally, CASP8AP2, CD36, ITGAL, NUMB, OLR1, PIAS-1, RNASEL, RTN4RL2 and THBS1 were identified for the first time as being associated to the active phase of RRMS.
Conclusions:The analysis of the JNK-dependent apoptosis pathway can provide biomarkers for activated lymphocytes in the active phase of RRMS and a gene expression signature for disease status. The reported results might be useful to stratify patients, thereby supporting the development of novel therapies.
PenderMPWolfeNP. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Intern Med J2002; 32: 554–563.
2.
ChenLBrosnanCF. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol2006; 176: 3115–3126.
3.
OkudaYSakodaSFujimuraHYanagiharaT. The effect of apoptosis inhibitors on experimental autoimmune encephalomyelitis: apoptosis as a regulatory factor. Biochem Biophys Res Commun2000; 267: 826–830.
4.
ZhouJZhangJSMaBLMamulaMJ. Experimental autoimmune encephalomyelitis in the Wistar rat: dependence of MBP-specific T cell responsiveness on B7 costimulation. Autoimmunity2002; 35: 191–199.
5.
OkudaYOkudaMBernardCC. The suppression of T cell apoptosis influences the severity of disease during the chronic phase but not the recovery from the acute phase of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol2002; 131: 115–125.
6.
JuliàEMontalbanXAl-ZayatHIssazadeh-NavikasSGoertschesRMartinR. Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. J Neuroimmunol2006; 180: 147–158.
7.
ChervonskyAV. Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol1999; 11: 684–688.
8.
SegalBMCrossAH. Fas(t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelination. Neurology2000; 55: 906–907.
9.
ShariefMK. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J Neuroimmunol2000; 109: 236–243.
10.
ZippFMartinRLichtenfelsRRothWDichgansJKrammerPH. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J Immunol1997; 159: 2108–2115.
11.
AchironAGurevichMFriedmanNKaminskiNMandelM. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol2004; 55: 410–417.
12.
ShariefMKMatthewsHNooriMA. Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis. J Neuroimmunol2003; 134: 158–165.
13.
CobbMHGoldsmithEJ. How MAP kinases are regulated. J Biol Chem1995; 270: 14843–14846.
14.
BarrRKBogoyevitchMA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol2001; 33: 1047–1063.
15.
RaineCSTraugottU. Experimental autoimmune demyelination. Chronic relapsing models and their therapeutic implications for multiple sclerosis. Ann N Y Acad Sci1984; 436: 33–51.
16.
SlevinMKrupinskiJSlowikARubioFSzczudlikAGaffneyJ. Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. Neuroreport2000; 11: 2759–2764.
17.
ShinTAhnMJungKHeoSKimDJeeY. Activation of mitogen-activated protein kinases in experimental autoimmune encephalomyelitis. J Neuroimmunol2003; 140: 118–125.
18.
GuptaSBarrettTWhitmarshAJCavanaghJSlussHKDérijardB. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J1996; 15: 2760–2770.
19.
RincónMWhitmarshAYangDDWeissLDérijardBJayarajP. The JNK pathway regulates the in vivo deletion of immature CD4(+)CD8(+) thymocytes. J Exp Med1998; 188: 1817–1830.
20.
YangDDConzeDWhitmarshAJBarrettTDavisRJRincónM. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity1998; 9: 575–585.
21.
ConzeDKrahlTKennedyNWeissLLumsdenJHessP. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J Exp Med2002; 195: 811–823.
22.
FlavellRALiBDongCLuHTYangDDEnslenH. Molecular basis of T-cell differentiation. Cold Spring Harb Symp Quant Biol1999; 64: 563–571.
23.
FlavellRADongCDavisRJ. Signaling and cell death in lymphocytes. Inflamm Res2002; 51: 80–82.
24.
GaillardPJeanclaude-EtterIArdissoneVArkinstallSCambetYCampsM. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem2005; 48: 4596–4607.
25.
PantaleoGKoenigSBaselerMLaneHCFauciAS. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol1990; 144: 1696–1704.
26.
OkudaYOkudaMApatoffBRPosnettDN. The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis. J Neurol Sci2005; 235: 11–17.
27.
JensenJLangkildeARFenstCNicolaisenMSRoedHGChristiansenM. CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol2004; 149: 202–209.
28.
GilliFMarnettoFCaldanoMSalaAMalucchiSCapobiancoM. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler2006; 12: 47–57.
29.
SatohJNakanishiMKoikeFMiyakeSYamamotoTKawaiM. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis2005; 18: 537–550.
KleiterIPedréXMuellerAMPoeschlPCouillard-DespresSSprussT. Inhibition of Smad7, a negative regulator of TGF-beta signaling, suppresses autoimmune encephalomyelitis. J Neuroimmunol2007; 187: 61–73.
32.
AndersonACKitchensEAChanSWSt HillCJanYNZhongW. The Notch regulator Numb links the Notch and TCR signaling pathways. J Immunol2005; 174: 890–897.
33.
LopatinskayaLZwemmerJUitdehaagBLucasKPolmanCNagelkerkenL. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult Scler2006; 12: 704–709.
34.
TeutschSMBoothDRBennettsBHHeardRNStewartGJ. Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis. Eur J Hum Genet2003; 11: 509–515.
35.
MahadDCallahanMKWilliamsKAUboguEEKivisäkkPTuckyB. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain2006; 129: 212–223.
36.
SimpsonJRezaiePNewcombeJCuznerMLMaleDWoodroofeMN. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol2000; 108: 192–200.
37.
Infante-DuarteCWeberAKrätzschmarJProzorovskiTPikolSHamannI. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J2005; 19: 1902–1904.
SospedraMMartinR. Immunology of multiple sclerosis. Annu Rev Immunol2005; 23: 683–747.
41.
BettelliEKornTKuchrooVK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol2007; 19: 652–657.
42.
KornTOukkaMKuchrooVBettelliE. Th17 cells: effector T cells with inflammatory properties. Semin Immunol2007; 19: 362–371.
43.
LuBYuHChowCLiBZhengWDavisRJ. GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity2001; 14: 583–590.
44.
LuBFerrandinoAFFlavellRA. Gadd45beta is important for perpetuating cognate and inflammatory signals in T cells. Nat Immunol2004; 5: 38–44.
45.
SabatRWallaceEEndesfelderSWolkK. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets2007; 11: 601–612.
46.
WangJWangGSunBLiHMuLWangQ. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun2008; 30: 222–229.
